Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402296 | 0.91 | RNASE1 (0.53) | RNASE1TYMSTK1 | |
| SCHEMBL23996825 | 0.91 | RNASE1 (0.53) | RNASE1TYMSTK1 | |
| SCHEMBL30287884 | 0.91 | RNASE1 (0.53) | RNASE1TYMSTK1 | |
| SCHEMBL23045153 | 0.90 | RNASE1 (0.57) | RNASE1TYMSTK1TYMP | |
| SCHEMBL5531136 | 0.90 | RNASE1 (0.56) | RNASE1TYMSTK1TYMP | |
| SCHEMBL2379935 | 0.90 | RNASE1 (0.56) | RNASE1TYMSTK1TYMP | |
| SCHEMBL5531135 | 0.90 | RNASE1 (0.56) | RNASE1TYMSTK1TYMP | |
| SCHEMBL17230824 | 0.89 | RNASE1 (0.53) | RNASE1TYMSTK1TYMP | |
| SCHEMBL8749986 | 0.88 | RNASE1 (0.68) | RNASE1TYMSTK1TYMP | |
| SCHEMBL6830771 | 0.87 | RNASE1 (0.51) | RNASE1TYMSTK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919437-B1 | Synthetic methods and intermediates for triester oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-6861514-B2 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6846922-B1 | Reacting phosphoramidite with hydroxyl group of nucleoside or oligonucleotide linked to solid support in presence of activating reagent comprising at least one pyridinium salt and at least one substituted imidazole | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6642373-B2 | Phosphitylating using pyridinium salt activators; forming phosphorate or phosphorothioate intersugar linkages | ISIS PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | IONIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-6335434-B1 | FOR INCREASED MEMBRANE PERMEABILITY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC., | 2002-01-01 | — | — | US | disclosed |
| US-6274725-B1 | PROVIDING COMPOUND HAVING A HYDROXYL GROUP; REACTING WITH PHOSPHITYLATING REAGENT IN THE PRESENCE OF A PYRIDINUM SALT IN A SOLVENT UNDER CONDITIONS OF TIME, TEMPERATURE AND PRESSURE TO YIELD PHOSPHITYLATED COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | MTHFD1, DHFR, FOLR1 | RNASE1 1110/4885TYMS 9/4885TK1 121/4885 |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | ITPA, NUDT1, TYMP | RNASE1 72/4885TYMS 21/4885TK1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.